Citi analyst David Lebowitz reiterated a Buy rating and $86.00 price target on Cytokinetics (NASDAQ: CYTK)The analyst comments "Cytokinetics announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE